Abstracts tagged "Disease Activity"

Abstract Number: 1152 • 2017 ACR/ARHP Annual Meeting
Interleukin-37 As an Independent Disease Activity Marker of Adult-Onset Still’s Disease
Seoung Wan Nam¹, SuMan Kang², Hyoungyoung Kim³, Ga-Young Ahn⁴, Min Jung Kim³ and Dae-Hyun Yoo¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Diagnosis and accurate measurement of disease activity in adult-onset Still¡¯s disease (AOSD) are still challenging due to its heterogeneous clinical manifestations and the lack…
Abstract Number: 1538 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Early Versus Delayed Anti-TNF-α Treatment in Axial Spondyloarthritis
Herman F Mann¹, Jakub Zavada², Šárka Forejtová³, Lenka Szczukova⁴, Zlatuše Křístková⁴ and Karel Pavelka¹, ¹ATTRA, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague, Czech Republic, ⁴Institute of Biostatistics and Analyses. Faculty of Medicine, Masaryk University, Brno, Czech Republic
Background/Purpose: Anti-TNF-α agents are the mainstay of pharmacotherapy for patients with axial spondyloarthritis (AxSpA) who failed treatment with NSAIDs. A little is known about the…
Abstract Number: 1820 • 2017 ACR/ARHP Annual Meeting
Sustained Effectiveness after Remission Induction with Methotrexate and Step-Down Glucocorticoids in Patients with Early Rheumatoid Arthritis Following a Treat-to-Target Strategy after 2 Years
Veerle Stouten¹, Johan Joly², Diederik De Cock¹, Sofia Pazmino¹, Kristien Van der Elst^2,3, René Westhovens^1,2 and Patrick Verschueren^1,2, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Remission induction with methotrexate (MTX) and a moderate-dose, step-down scheme of Glucocorticoids (GC), (COBRA Slim strategy), showed equally high remission rates at year 1…
Abstract Number: 2312 • 2017 ACR/ARHP Annual Meeting
Prevalence of Serum 14-3-3η (eta) in Juvenile Idiopathic Arthritis
Iris Reyhan¹, Olga S. Zhukov², Robert J. Lagier³, Robert Bridgforth⁴, Gary J Williams⁵, Joanna M. Popov², Stanley J. Naides² and Andreas Reiff⁶, ¹Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴Quest Diagnostics Nichols Institute, clemente, CA, ⁵Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ⁶Children’s Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease. Currently, diagnosis is based on clinical assessment defined by the International League of…
Abstract Number: 2533 • 2017 ACR/ARHP Annual Meeting
Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Simultaneous control of joint symptoms and degree of skin involvement has been linked to improvement in health-related quality of life in patients with coexistent…
Abstract Number: 2910 • 2017 ACR/ARHP Annual Meeting
Comparison of Clinical and Ultrasound Measures of Disease Activity in a Large National ‘Real Life’ Cohort of RA Patients
Pascal Zufferey¹, Delphine Couvoisier², Hans Ruedi Ziswiler³, Laure Brulhart⁴, Giorgio Tamborrini⁵, Michael Nissen⁶, Adrian Ciurea⁷, Burkhard Moeller⁸, Maria Antonietta D'Agostino^9,10 and Axel Finckh², ¹Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ²geneva university hospital, Geneva, Switzerland, ³Osteorheuma, Bern, Switzerland, ⁴médecine, hôpital neuchateulois, La chaux de fond, Switzerland, ⁵UZR, Basel, Switzerland, ⁶rheumatology, geneva university hospital, Geneva, Switzerland, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁸Department for Rheumatology, Immunology and Allergology, University Hospital of Bern, Bern, Switzerland, ⁹Department of Rheumatology, Assistance publique-Hôpitaux de Paris Ambroise Paré Hospital, Boulogne-Billancourt , Université Versailles Saint Quentin en Yvelines, Paris, France, ¹⁰University of Paris, Paris, France
Background/Purpose: Clinical measures of disease activity, such as the DAS-score and ultrasound (US) scores of disease activity can be sometimes yield discordant results. Little research…
Abstract Number: 135 • 2017 ACR/ARHP Annual Meeting
Comorbidity Measures Differentially Predict Longitudinal Disease Activity, Remission, and Disability in Rheumatoid Arthritis
Bryant R. England¹, Harlan Sayles², Kaleb Michaud², Grant Cannon³, Andreas Reimold⁴, Liron Caplan⁵, Gail S. Kerr⁶, Namrata Singh⁷, Gleb Haynatzki⁸, Michael D. George⁹, Joshua Baker¹⁰ and Ted R. Mikuls¹¹, ¹Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴Hospital of Southern Norway, Kristiansand, Norway, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶VAMC, Georgetown University, Washington, DC, ⁷Internal Medicine, University of Iowa Hospitals and Clinics and Iowa City VA, Iowa City, IA, ⁸Biostatistics, University of Nebraska Medical Center, Omaha, NE, ⁹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁰Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹¹Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Comorbidity frequently complicates rheumatoid arthritis (RA) leading to poor long-term outcomes. However, whether comorbidity influences measures of RA activity over time is less well…
Abstract Number: 692 • 2017 ACR/ARHP Annual Meeting
High Plasma Factor XIII Transglutaminase Activity Inversely Correlates with SLE Disease Activity Yet Associates with Higher Carotid Artery IMT and Low CD14+CD16+ Monocyte Levels
Brian Skaggs¹, Isao Matsuura², Elaine Lourenco¹, Eloise Olmos³, Jennifer M. Grossman¹ and Maureen A. McMahon¹, ¹University of California-Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Department of Rheumatology, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan, ³Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The transglutaminase Factor XIII (FXIII) stabilizes blood clots through crosslinking fibrin lysine and glutamine residues at the end of the complement cascade. Enzymatic activity…
Abstract Number: 1232 • 2017 ACR/ARHP Annual Meeting
The Perceived Impact of Recent-Onset Psoriatic Arthritis Is Different between Genders: A Spanish Multicenter Experience
Rubén Queiro¹, Ana Laiz², Carlos Alberto Montilla-Morales³, Eva Galindez-Agirregoikoa⁴, Juan J. Bethencourt⁵ and Daniel Seoane⁶, ¹Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ²Rheumatology, HU. Santa Creu i San Pau, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁴Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, ⁵Rheumatology, HU. Canarias, Sta. Cruz de Tenerife, Spain, ⁶Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain
Background/Purpose: Some studies point to a differential clinical expression between men and women with PsA, but the information on gender differences is very scarce in…
Abstract Number: 1541 • 2017 ACR/ARHP Annual Meeting
First Line Biological Treatment in Ankylosing Spondylitis, Prescription Rates, Baseline Demographics and Disease Activity. a Collaboration between Biological Registers in the Five Nordic Counties
Bente Glintborg¹, Ulf Lindström², Kalle Aaltonen³, Eirik K Kristianslund⁴, Björn Gudbjornsson⁵, Katerina Chatzidionysiou², Johan Askling⁶, Dan Nordström⁷, Merete Lund Hetland⁸, Daniela Di Giuseppe⁹, Lene Dreyer¹⁰, Tanja Schjødt Jørgensen¹¹, Lars Erik Kristensen¹⁰, Kari Eklund³, Gerdur Grondal¹², Sofia Ernestam², Jaana Joensuu³, Tore K Kvien¹³, Elisabeth Lie¹³, Karen M Fagerli¹³, Arni Jon Geirsson¹², Helgi Jonsson¹² and Lennart TH Jacobsson¹⁴, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²On behalf of the SRQ/ARTIS registry, Stockholm, Sweden, ³On behalf of the ROB-FIN registry, Helsinki, Finland, ⁴Dept. of Rheumatology, On behalf of the NOR-DMARD registry, Oslo, Norway, ⁵ICEBIO, Reykjavik, Iceland, Reykjavik, Iceland, ⁶Unit of Clinical Epidemiology, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁷ROB-FIN, Helsinki, Finland, Helsinki, Finland, ⁸The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, ⁹Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁰On behalf of the DANBIO registry, Copenhagen, Denmark, ¹¹On behalf of the DANBIO registry, Copenhagen F, Denmark, ¹²On behalf of the ICEBIO registry, Reykjavik, Iceland, ¹³On behalf of the NOR-DMARD registry, Oslo, Norway, ¹⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Large-scale observational cohorts identified in national biological registries may be used to study effectiveness of biological disease modifying drugs (bDMARDs) in ankylosing spondylitis (AS).…
Abstract Number: 1825 • 2017 ACR/ARHP Annual Meeting
Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis
Michaela Koehm¹, Michael Hofmann², Rasmus Lüthje², Matthew McIntosh³, Varghese Abraham³, Cem Gabay⁴, Arthur Kavanaugh⁵, Harald Burkhardt⁶ and Frank Behrens⁶, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ³Genentech, San Francisco, CA, ⁴SCQM, Geneva, Switzerland, Geneva, Switzerland, ⁵Medicine, University of California, San Diego, La Jolla, CA, ⁶Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany
Background/Purpose: Fluctuations in disease activity due to short-term situational effects and measurement errors are important considerations for evaluation of individual clinically meaningful therapeutic response in…
Abstract Number: 2336 • 2017 ACR/ARHP Annual Meeting
Expression of Myxovirus-Resistance Protein a: A Possible Marker of Muscular Disease Activity in Juvenile Dermatomyositis
Sirisucha Soponkanaporn¹, Claire Deakin², Lucy Marshall², Cerise Johnson², Peter Schutz¹ and Lucy R Wedderburn², ¹Infection Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom, ²Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic autoimmune myopathy characterized by proximal muscle weakness and typical skin rashes. Type I interferon (IFN) gene expression in…
Abstract Number: 2534 • 2017 ACR/ARHP Annual Meeting
the Relationship between Biological Therapy, Work Productivity, and Activity Impairment in Patients with Psoriatic Arthritis: Prospective Multicentre Observational Study
Jiri Stolfa¹, Tomas Mlcoch², Jan Tuzil², Liliana Sedova³, Jitka Jircikova⁴, Monika Gregova⁵, Tomas Dolezal⁴ and Karel Pavelka⁶, ¹Instituite of Rheumatology Prague, Rheumatology, Prague, Czech Republic, ²Institute of Health Economics and Technology Assessment (iHETA), Statistician, Prague, Czech Republic, ³Institute of Rheumatology Prague, rheumatologist, Prague, Czech Republic, ⁴Institute of Health Economics and Technology Assessment (iHETA), statistician, Prague, Czech Republic, ⁵Instituite of Rheumatology Prague, rheumatologist, Prague, Czech Republic, ⁶Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Psoriatic arthritis (PsA) is a progressive disease bringing substantial socioeconomic burden. Gradual loss of productivity (PL) and daily activities can be modified by effective…
Abstract Number: 2916 • 2017 ACR/ARHP Annual Meeting
The Presence of a Large Number of Autoantibodies at Baseline Is Favourable for Early Treatment Response but Unfavourable for Drug-Free Remission in RA Patients
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², R.J. Goekoop³, I Speyer⁴, TWJ Huizinga¹, CF Allaart¹, REM Toes¹ and Diane van der Woude⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Haga Hospital, The Hague, Netherlands, ⁴Haaglanden Medical Center, The Hague, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The autoantibody response of seropositive RA is very diverse and consists of various numbers of isotypes and antibodies to multiple post-translational modifications. It is…
Abstract Number: 144 • 2017 ACR/ARHP Annual Meeting
Are RA Patients at a Higher Risk for Car Accidents?
Kaleb Michaud^1,2, Sofia Pedro¹ and Ted R. Mikuls³, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Automobile driving is an important instrumental activity of daily living with heightened importance among arthritis sufferers who are disproportionately reliant on driving for the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].